TABLE 2.
Initial and follow-up anti-cancer regimens for patients with ILD-LC.
| Stage of treatment# | Totol | 1st- (n,%&) | 2nd- (n,%) | ≥3rd-or more (n,%) |
| N | 140 | 140 (100.0) | 78 (55.7) | 32 (22.8) |
| Surgery | 25 | 25 (17.9) | 0 (0) | 0 (0) |
| Chemotherapy | 109 | 89 (63.6) | 45 (57.7) | 23 (71.9) |
| Interventional therapy | 6 | 2 (1.4) | 3 (3.8) | 1 (3.1) |
| Radiotherapy | 35 | 10 (7.1) | 22 (28.2) | 3 (9.4) |
| Anti-angiogenic therapy※ | 29 | 13 (9.3) | 10 (12.8) | 8 (25.0) |
| Targeted therapy€ | 20 | 12 (8.6) | 8 (10.3) | 3 (9.4) |
| Immunotherapy | 8 | 5 (3.6) | 3 (3.8) | 1 (3.1) |
| Others€ | 7 | 7 (5.0) | 0 (0) | 0 (0) |
#Patients can receive more than one anti-cancer regimens at every stage of treatment. &The proportion of a regimen in the treatment stage to total events of the regimen. ※Anti-angiogenic agents include 11 cases of bevacizumab, 3 cases of apatinib, 5 cases of anlotinib, 9 cases of nintedanib, 1 case of recombinant human endostatin. €There were 11 patients with EGFR mutations,10 in the first stage and 1 in the second stage. Two patients in the first stage received EGFR-TKIs without confirming the EGFR status. The remaining patients in the second- and above stage were at an unknown EGFR status for lacking records. €Oral anti-cancer drugs.